Literature DB >> 14983964

Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening.

S Ciatto1, M Zappa, A Villers, A Paez, S J Otto, A Auvinen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14983964     DOI： 10.1111/j.1464-410x.2003.04407.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  13 in total

1.  What explains the differences between centres in the European screening trial? A simulation study.

Authors:  Jaakko Nevalainen; Ulf-Håkan Stenman; Teuvo L Tammela; Monique Roobol; Sigrid Carlsson; Kirsi Talala; Fritz H Schröder; Anssi Auvinen
Journal:  Cancer Epidemiol       Date:  2016-11-24       Impact factor: 2.984

2.  The Impact of Design and Performance in Prostate-Specific Antigen Screening: Differences Between ERSPC Centers.

Authors:  Eveline A M Heijnsdijk; Jan Adolfsson; Anssi Auvinen; Monique J Roobol; Jonas Hugosson; Harry J de Koning
Journal:  Eur Urol       Date:  2019-04-26       Impact factor: 20.096

3.  Serum total and HDL cholesterol and risk of prostate cancer.

Authors:  Alison M Mondul; Stephanie J Weinstein; Jarmo Virtamo; Demetrius Albanes
Journal:  Cancer Causes Control       Date:  2011-09-14       Impact factor: 2.506

Review 4.  The current evidence on statin use and prostate cancer prevention: are we there yet?

Authors:  Mahmoud A Alfaqih; Emma H Allott; Robert J Hamilton; Michael R Freeman; Stephen J Freedland
Journal:  Nat Rev Urol       Date:  2016-10-25       Impact factor: 14.432

5.  Prostate-cancer mortality at 11 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Alvaro Páez; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Sigrid Carlsson; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Paula M Kujala; Bert G Blijenberg; Ulf-Hakan Stenman; Andreas Huber; Kimmo Taari; Matti Hakama; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2012-03-15       Impact factor: 91.245

6.  The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.

Authors:  Harry J de Koning; Roman Gulati; Sue M Moss; Jonas Hugosson; Paul F Pinsky; Christine D Berg; Anssi Auvinen; Gerald L Andriole; Monique J Roobol; E David Crawford; Vera Nelen; Maciej Kwiatkowski; Marco Zappa; Marcos Luján; Arnauld Villers; Tiago M de Carvalho; Eric J Feuer; Alex Tsodikov; Angela B Mariotto; Eveline A M Heijnsdijk; Ruth Etzioni
Journal:  Cancer       Date:  2017-12-06       Impact factor: 6.860

7.  Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.

Authors:  Roman Gulati; John L Gore; Ruth Etzioni
Journal:  Ann Intern Med       Date:  2013-02-05       Impact factor: 25.391

Review 8.  Rationale for statins in the chemoprevention of prostate cancer.

Authors:  Robert J Hamilton; Stephen J Freedland
Journal:  Curr Urol Rep       Date:  2008-05       Impact factor: 3.092

Review 9.  Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.

Authors:  G Pron
Journal:  Ont Health Technol Assess Ser       Date:  2015-05-01

Review 10.  What do the screening trials really tell us and where do we go from here?

Authors:  Ruth D Etzioni; Ian M Thompson
Journal:  Urol Clin North Am       Date:  2014-02-19       Impact factor: 2.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.